miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

XRP Price: Why Is XRP Not Going Up? The 3 Things Holding XRP Back

View original at finance.yahoo.com
XRP Price: Why Is XRP Not Going Up? The 3 Things Holding XRP Back Quick Read XRP tracks Bitcoin with a 0.80 correlation, so with BTC stuck between $65,000 and $75,000 and dominance above 58%, XRP can’t rally regardless of its own fundamentals…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • XRP swings about 1.8 times more than Bitcoin in either direction

    60% confidence
  • XRP whales have cashed out an estimated $6 billion since the $3.65 peak

    60% confidence
  • 60% of XRP's circulating supply is held at a loss

    60% confidence
  • XRP ETF weekly inflows collapsed from $200 million at launch to under $2 million

    60% confidence
  • Bitcoin ETFs have bled over $3.8 billion in outflows since January

    60% confidence
  • XRP tracks Bitcoin roughly 80% of the time with a correlation of 0.80

    60% confidence
  • 84% of XRP ETF money is coming from retail investors

    60% confidence
  • Futures markets aren't pricing in a Fed rate cut before December at the earliest

    60% confidence

Data points we hold from this source

XRP · return from peak-60 percent
XRP · supply held at loss60 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com